Search company, investor...

Predict your next investment

GL Capital company logo
Private Equity
gl-investment.com

Investments

27

Portfolio Exits

9

Funds

5

About GL Capital

GL Capital is a healthcare-focused investment management private equity firm. It seeks opportunities in China's healthcare industry. The company was founded in 2009 and is based in Beijing, China.

Headquarters Location

China World Tower 2, No 1 Jian Guo Men Wai Avenue Unit 3001

Beijing, Beijing, 100004,

China

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest GL Capital News

Jinxin Group Successfully Introduces High-quality International Investors, Capital Group Private Markets and GL Capital

Oct 27, 2023

Close Cooperation of Industry Leader and Global Investors Accelerates the Pace of Corporate Development HONG KONG, June 8, 2018 - (ACN Newswire) - Chengdu Jinxin Healthcare Investment Management Group ("Jinxin Group" or the "Group"), a Sichuan-based international healthcare group, is pleased to announce that the ceremony for the completion of investments in JINXIN Medical Investment Group Limited ("JINXIN Healthcare"), the holding company of the maternity and psychiatry services segment under the Group, by Funds managed by Capital Group Private Markets (CGPM) and GL Capital, was held at Sichuan Jinxin Women & Children Hospital on 8 June 2018. Provincial and city leaders, including Mr. Peng Jie, Associate Counsel of the Health and Family Planning Commission of Sichuan Province, Mr. Wang Gian, District Mayor of Jinjiang District People's Government and Mr. Zhang Yi, Associate Counsel of the Health and Family Planning Commission of Chengdu, attended the ceremony and witnessed another successful introduction of leading global investors by the Jinxin Group, which was a firm step towards the completion of the Group's global strategic layout. This investment was led by CGPM, part of the U.S.-based Capital Group Companies. Founded in 1931, Capital Group Companies is one of the world's largest and most successful investment organizations and manages approximately US$1.7 trillion investment assets globally. GL Capital is a leading Greater China healthcare-focused, value-driven investment management group. Established in 2010 by the former Country President of Novartis China, Mr. Jeffrey Li, it manages various USD and RMB funds and has invested in over 40 companies as of the end of 2017. About 29% of the total shares of JINXIN Healthcare will be transferred to CGPM and GL Capital. Jinxin Group, the predecessor of which was established in [1951], operates business lines in maternity and psychiatry services, in-vitro fertility (IVF) services and elderly care, with a goal to create synergies among them and meet China's growing healthcare demand. Its subsidiary, JINXIN Healthcare is one of the largest obstetrics and gynecology hospital chains in Sichuan Province which has a population of 87 million. In 2017 it completed about 20,000 maternity deliveries. JINXIN Healthcare's flagship hospital, Sichuan Jinxin Women's and Children's Hospital is Asia's largest single-specialty hospital that has passed the international JCI accreditation and focuses on serving the growing mid- and high-end market segments with its top-notch team of medical experts, advanced clinical technologies and equipment, and state-of-art hospital facility. Chairman of Jinxin Group said, "As a leading private healthcare enterprise in China, Jinxin Group always strives to enhance our overall competitiveness. The introduction of these two high-quality institutional investors into JINXIN Healthcare demonstrates their recognition of the business segment's market leadership and value, as well as achieves for us institutionalization and diversification of the shareholder base. They will help us further raise the governance standards and gain access to the capital market. We believe they can also bring valuable global industry resources and expertise to our close partnership." Mr. Nick Chen, Partner of CGPM, commented: "Given our continuous focus and track record in the healthcare sector in Asia, we are very excited about our partnership with JINXIN Healthcare. The fruit of the hard work of several generations over 67 years, JINXIN Healthcare has become a rare privately-owned healthcare company in China that is able to compete with the best local public hospitals and even take a leading position in the medical specialties it operates in. The country's ongoing healthcare reform and urban consumption upgrade trend will drive more market demand growth. We believe JINXIN Healthcare is well positioned to capture this historic opportunity." Mr. Jeffrey Li, the Founder and CEO of GL Capital, indicated, "The cooperation with such outstanding enterprise like Jinxin Group has always been the investment philosophy of GL Capital. JINXIN Healthcare is a leading healthcare group in Southwest China, and has already built up its excellent brand reputation in the areas of maternity, psychiatry and other medical services. We believe that this transaction is only the beginning of the cooperative development for all parties, and GL Capital will, as always, provide value-added services to our invested companies and help promote the development of the healthcare industry in China." Looking into the future, the Group will continue to seize opportunities in key markets, deepen the strategic layout of globalization and increase its international competitiveness, thereby accelerating corporate development and strengthening its three pillar businesses for the creation of greater value for its consumers and stakeholders. About Chengdu Jinxin Healthcare Investment Management Group Chengdu Jinxin Healthcare Investment Management Group, the predecessor of which was established in 1951, is renowned for its three pillar businesses of maternity and psychiatry services, in-vitro fertility (IVF) services and elderly care. After 67 years of development, the Group has become one of the leading private healthcare groups in China. The Group is also one of the first batch of healthcare institutions in Sichuan Province approved by National Health Ministry to carry out the human assisted reproductive technology. In terms of the number of IVF cycles, the Group is amid top five in China and ranks first among private providers. Since 2016, high-quality strategic investors including Warburg Pincus and Goldstone Haorui Investment under CITIC Securities have been successively introduced into its IVF segment. About Capital Group Private Markets Capital Group Private Markets (CGPM) is part of Capital Group, one of the world's most successful investment institutions founded in 1931, and manages approximately US$1.7 trillion in assets. Over the last two decades, CGPM has invested over US$2 billion in emerging markets in Asia through its private equity funds. CGPM partners in particular with leading companies in the healthcare, consumer and business services sectors, including those with disruptive and/or technology-enabled business models. About GL Capital Established in 2010, GL Capital is a leading Greater China healthcare-focused, value-driven investment management group. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies.

GL Capital Investments

27 Investments

GL Capital has made 27 investments. Their latest investment was in Sangon Biotech as part of their Private Equity on April 4, 2023.

CBI Logo

GL Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/19/2023

Private Equity

Sangon Biotech

$290M

Yes

2

11/16/2022

Series A

Asia Pacific Medical Group

Yes

2

6/7/2022

Seed VC - II

Wuxi NEST Biotechnology

Yes

3

6/7/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/17/2022

Series A

Subscribe to see more

Subscribe to see more

10

Date

4/19/2023

11/16/2022

6/7/2022

6/7/2022

1/17/2022

Round

Private Equity

Series A

Seed VC - II

Series B

Series A

Company

Sangon Biotech

Asia Pacific Medical Group

Wuxi NEST Biotechnology

Subscribe to see more

Subscribe to see more

Amount

$290M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

3

10

10

GL Capital Portfolio Exits

9 Portfolio Exits

GL Capital has 9 portfolio exits. Their latest portfolio exit was Biokin Pharmaceutical on January 06, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/6/2023

IPO

$99M

Public

2

11/22/2022

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

3/22/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2021

IPO - II

Subscribe to see more

$99M

Subscribe to see more

10

6/29/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/6/2023

11/22/2022

3/22/2022

3/3/2021

6/29/2020

Exit

IPO

Reverse Merger

IPO

IPO - II

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

GL Capital Acquisitions

3 Acquisitions

GL Capital acquired 3 companies. Their latest acquisition was Foryou Medical on March 21, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/21/2023

Grant

$99M

Acq - Fin

1

10/13/2017

Subscribe to see more

$99M

Subscribe to see more

10

3/15/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/21/2023

10/13/2017

3/15/2017

Investment Stage

Grant

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

1

10

10

GL Capital Fund History

5 Fund Histories

GL Capital has 5 funds, including GL Capital China Opportunities Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/15/2023

GL Capital China Opportunities Fund IV

$25M

1

12/31/2016

GL China Opportunities Fund II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2009

GL Capital Fund

Subscribe to see more

Subscribe to see more

$99M

10

GL China Opportunities Fund III LP

Subscribe to see more

Subscribe to see more

10

GL YARD INVESTMENT L.P.

0

Closing Date

2/15/2023

12/31/2016

12/31/2009

Fund

GL Capital China Opportunities Fund IV

GL China Opportunities Fund II

GL Capital Fund

GL China Opportunities Fund III LP

GL YARD INVESTMENT L.P.

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$25M

$99M

$99M

Sources

1

10

10

10

0

GL Capital Team

1 Team Member

GL Capital has 1 team member, including current Founding Partner, Zhenfu Li.

Name

Work History

Title

Status

Zhenfu Li

Founding Partner

Current

Name

Zhenfu Li

Work History

Title

Founding Partner

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.